Logo image of VOR

VOR BIOPHARMA INC (VOR) Stock Fundamental Analysis

NASDAQ:VOR - Nasdaq - US9290331084 - Common Stock - Currency: USD

2.18  +0.07 (+3.32%)

After market: 2.19 +0.01 (+0.46%)

Fundamental Rating

2

Taking everything into account, VOR scores 2 out of 10 in our fundamental rating. VOR was compared to 551 industry peers in the Biotechnology industry. VOR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. VOR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year VOR has reported negative net income.
VOR had a negative operating cash flow in the past year.
VOR had negative earnings in each of the past 5 years.
In the past 5 years VOR always reported negative operating cash flow.
VOR Yearly Net Income VS EBIT VS OCF VS FCFVOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -108.49%, VOR is not doing good in the industry: 78.22% of the companies in the same industry are doing better.
VOR has a worse Return On Equity (-179.50%) than 64.97% of its industry peers.
Industry RankSector Rank
ROA -108.49%
ROE -179.5%
ROIC N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
VOR Yearly ROA, ROE, ROICVOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

VOR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VOR Yearly Profit, Operating, Gross MarginsVOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for VOR has been increased compared to 1 year ago.
The number of shares outstanding for VOR has been increased compared to 5 years ago.
There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VOR Yearly Shares OutstandingVOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
VOR Yearly Total Debt VS Total AssetsVOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -5.77, we must say that VOR is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VOR (-5.77) is worse than 62.43% of its industry peers.
VOR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -5.77
ROIC/WACCN/A
WACCN/A
VOR Yearly LT Debt VS Equity VS FCFVOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.88 indicates that VOR has no problem at all paying its short term obligations.
VOR has a Current ratio of 3.88. This is comparable to the rest of the industry: VOR outperforms 45.01% of its industry peers.
A Quick Ratio of 3.88 indicates that VOR has no problem at all paying its short term obligations.
With a Quick ratio value of 3.88, VOR perfoms like the industry average, outperforming 47.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.88
VOR Yearly Current Assets VS Current LiabilitesVOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.17% over the past year.
EPS 1Y (TTM)15.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VOR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.66% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y58.17%
EPS Next 2Y31.13%
EPS Next 3Y11.76%
EPS Next 5Y17.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VOR Yearly Revenue VS EstimatesVOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M
VOR Yearly EPS VS EstimatesVOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VOR Price Earnings VS Forward Price EarningsVOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VOR Per share dataVOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.13%
EPS Next 3Y11.76%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VOR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VOR BIOPHARMA INC

NASDAQ:VOR (8/5/2025, 5:35:50 PM)

After market: 2.19 +0.01 (+0.46%)

2.18

+0.07 (+3.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners48.76%
Inst Owner Change-0.29%
Ins Owners0.57%
Ins Owner Change24.89%
Market Cap272.41M
Analysts71.11
Price Target1.2 (-44.95%)
Short Float %20.19%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.55%
Min EPS beat(2)-52.48%
Max EPS beat(2)-12.62%
EPS beat(4)2
Avg EPS beat(4)-15.2%
Min EPS beat(4)-52.48%
Max EPS beat(4)2.83%
EPS beat(8)3
Avg EPS beat(8)-7.73%
EPS beat(12)5
Avg EPS beat(12)-4.02%
EPS beat(16)8
Avg EPS beat(16)-1.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)271.01%
PT rev (3m)-86.73%
EPS NQ rev (1m)-95.37%
EPS NQ rev (3m)-83.54%
EPS NY rev (1m)0%
EPS NY rev (3m)21.85%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.12
P/tB 4.12
EV/EBITDA N/A
EPS(TTM)-1.51
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS0
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108.49%
ROE -179.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.36%
ROA(5y)-53.18%
ROE(3y)-78.63%
ROE(5y)-74.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.88
Altman-Z -5.77
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)123.83%
Cap/Depr(5y)265.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.22%
EPS Next Y58.17%
EPS Next 2Y31.13%
EPS Next 3Y11.76%
EPS Next 5Y17.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.9%
OCF growth 3YN/A
OCF growth 5YN/A